INTEGRATED DIAGNOSIS OF LUNG CANCER - HOW CAN WE OBTAIN ALL THE USEFUL DIAGNOSTIC INFORMATION WITH A SMALL BIOPSY?

WEDNESDAY, MAY 17, 2017

Hôpital Charles -Le Moyne
Room HN-106
12:00 to 13:00
Videoconference Request: vspo@mcgill.ca

Hôpital Notre-Dame
Amphithéâtre Deschamps
17:00 to 18:00

THURSDAY, MAY 18, 2017

MUHC-GLEN
Room D03.6020
9:00 to 10:00
Videoconference Request: vspo@mcgill.ca

Jewish General Hospital
Room H-433
12:00 to 13:00
Live on the Web! www.vpsolution.tv/vspo
Problems/Questions: 514 813-4510

LEARNING OBJECTIVES

• To understand the importance of molecular testing in the diagnosis and management of NSCLC
• To be familiarized with new technologies that allow for more comprehensive molecular diagnoses
• To appreciate how quantity of tissue impacts the molecular testing that can be done, and the trade-offs with minimizing procedural risks to patients
• To discuss ways that ensure maximal diagnostic value is obtained when limited tissue is available

This event is approved for up to 1 credit by the Office for Continuing Professional Development. The Office for CPD, Faculty of Medicine, McGill University is fully accredited by the Committee on Accreditation of Canadian Medical Education (CACME). This event is an Accredited Group Learning Activity as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada. Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at www.amaassn.org/go/internationalcme. Each physician should claim only credit commensurate with the extent of their participation in the activity. For more information, please visit our website at: http://www.medicine.mcgill.ca/oncology/speakers/speakers_visitingSpeakers.asp

This program has received an educational grant from:
AbbVie, Alexion, Amgen, Apobiologix, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, Eli Lilly, Gilead, Janssen, Lundbeck, Merck, Novartis, Pfizer, Roche, Seattle Genetics, Shire